Summary of this trial
This Phase 2 trial in patients with Melanoma is being sponsored by Melanoma Research Foundation Breakthrough Consortium. 180 individuals will be dosed with one or more of the following: Vemurafenib, Bevacizumab. Trial dates are from 1st March 2012 to 1st March 2015. The study is currently not yet recruiting.